TERT	B:C0754515
,	O
BRAF	O
and	O
NRAS	O
in	O
primary	O
thyroid	O
cancer	O
and	O
metastatic	O
disease	I:C0027627
.	O

TERT	O
,	O
BRAF	B:C1259929
and	O
NRAS	O
in	O
primary	O
thyroid	O
cancer	O
and	O
metastatic	O
disease	I:C0027627
.	O

TERT	O
,	O
BRAF	O
and	O
NRAS	B:C0079975
in	O
primary	O
thyroid	O
cancer	O
and	O
metastatic	O
disease	I:C0027627
.	O

TERT	O
,	O
BRAF	O
and	O
NRAS	O
in	O
primary	O
thyroid	O
cancer	O
and	O
metastatic	B:C0027627
disease	I:C0027627
.	O

Little	O
is	O
known	O
about	O
the	O
frequency	O
of	O
key	O
mutations	O
in	O
thyroid	B:C0007115
cancer	I:C0007115
metastases	O
and	O
its	O
relationship	O
with	O
the	O
primary	O
tumor	I:C0677930
genotype	O
.	O

Little	O
is	O
known	O
about	O
the	O
frequency	O
of	O
key	O
mutations	O
in	O
thyroid	O
cancer	I:C0007115
metastases	B:C0027627
and	O
its	O
relationship	O
with	O
the	O
primary	O
tumor	I:C0677930
genotype	O
.	O

Little	O
is	O
known	O
about	O
the	O
frequency	O
of	O
key	O
mutations	O
in	O
thyroid	O
cancer	I:C0007115
metastases	O
and	O
its	O
relationship	O
with	O
the	O
primary	B:C0677930
tumor	I:C0677930
genotype	O
.	O

To	O
evaluate	O
the	O
frequency	O
of	O
TERT	B:C1367342
promoter	O
(	O
TERT	O
promoter	I:C0314621
)	O
,	O
BRAF	O
and	O
NRAS	O
mutations	O
in	O
metastatic	O
thyroid	O
carcinomas	I:C0549473
,	O
analyzing	O
primary	O
thyroid	O
tumors	O
,	O
lymph	O
node	I:C0686619
metastases	I:C0686619
(	O
lymph	O
node	I:C0686619
metastases	I:C0686619
)	O
and	O
distant	O
metastases	I:C1269798
.	O

To	O
evaluate	O
the	O
frequency	O
of	O
TERT	O
promoter	B:C0314621
(	O
TERT	O
promoter	I:C0314621
)	O
,	O
BRAF	O
and	O
NRAS	O
mutations	O
in	O
metastatic	O
thyroid	O
carcinomas	I:C0549473
,	O
analyzing	O
primary	O
thyroid	O
tumors	O
,	O
lymph	O
node	I:C0686619
metastases	I:C0686619
(	O
lymph	O
node	I:C0686619
metastases	I:C0686619
)	O
and	O
distant	O
metastases	I:C1269798
.	O

To	O
evaluate	O
the	O
frequency	O
of	O
TERT	O
promoter	O
(	O
TERT	B:C0314621
promoter	I:C0314621
)	O
,	O
BRAF	O
and	O
NRAS	O
mutations	O
in	O
metastatic	O
thyroid	O
carcinomas	I:C0549473
,	O
analyzing	O
primary	O
thyroid	O
tumors	O
,	O
lymph	O
node	I:C0686619
metastases	I:C0686619
(	O
lymph	O
node	I:C0686619
metastases	I:C0686619
)	O
and	O
distant	O
metastases	I:C1269798
.	O

To	O
evaluate	O
the	O
frequency	O
of	O
TERT	O
promoter	O
(	O
TERT	O
promoter	I:C0314621
)	O
,	O
BRAF	B:C0812241
and	O
NRAS	O
mutations	O
in	O
metastatic	O
thyroid	O
carcinomas	I:C0549473
,	O
analyzing	O
primary	O
thyroid	O
tumors	O
,	O
lymph	O
node	I:C0686619
metastases	I:C0686619
(	O
lymph	O
node	I:C0686619
metastases	I:C0686619
)	O
and	O
distant	O
metastases	I:C1269798
.	O

To	O
evaluate	O
the	O
frequency	O
of	O
TERT	O
promoter	O
(	O
TERT	O
promoter	I:C0314621
)	O
,	O
BRAF	O
and	O
NRAS	B:C0027260
mutations	O
in	O
metastatic	O
thyroid	O
carcinomas	I:C0549473
,	O
analyzing	O
primary	O
thyroid	O
tumors	O
,	O
lymph	O
node	I:C0686619
metastases	I:C0686619
(	O
lymph	O
node	I:C0686619
metastases	I:C0686619
)	O
and	O
distant	O
metastases	I:C1269798
.	O

To	O
evaluate	O
the	O
frequency	O
of	O
TERT	O
promoter	O
(	O
TERT	O
promoter	I:C0314621
)	O
,	O
BRAF	O
and	O
NRAS	O
mutations	B:C1516197
in	O
metastatic	O
thyroid	O
carcinomas	I:C0549473
,	O
analyzing	O
primary	O
thyroid	O
tumors	O
,	O
lymph	O
node	I:C0686619
metastases	I:C0686619
(	O
lymph	O
node	I:C0686619
metastases	I:C0686619
)	O
and	O
distant	O
metastases	I:C1269798
.	O

To	O
evaluate	O
the	O
frequency	O
of	O
TERT	O
promoter	O
(	O
TERT	O
promoter	I:C0314621
)	O
,	O
BRAF	O
and	O
NRAS	O
mutations	O
in	O
metastatic	B:C0027627
thyroid	O
carcinomas	I:C0549473
,	O
analyzing	O
primary	O
thyroid	O
tumors	O
,	O
lymph	O
node	I:C0686619
metastases	I:C0686619
(	O
lymph	O
node	I:C0686619
metastases	I:C0686619
)	O
and	O
distant	O
metastases	I:C1269798
.	O

To	O
evaluate	O
the	O
frequency	O
of	O
TERT	O
promoter	O
(	O
TERT	O
promoter	I:C0314621
)	O
,	O
BRAF	O
and	O
NRAS	O
mutations	O
in	O
metastatic	O
thyroid	B:C0549473
carcinomas	I:C0549473
,	O
analyzing	O
primary	O
thyroid	O
tumors	O
,	O
lymph	O
node	I:C0686619
metastases	I:C0686619
(	O
lymph	O
node	I:C0686619
metastases	I:C0686619
)	O
and	O
distant	O
metastases	I:C1269798
.	O

To	O
evaluate	O
the	O
frequency	O
of	O
TERT	O
promoter	O
(	O
TERT	O
promoter	I:C0314621
)	O
,	O
BRAF	O
and	O
NRAS	O
mutations	O
in	O
metastatic	O
thyroid	O
carcinomas	I:C0549473
,	O
analyzing	O
primary	O
thyroid	O
tumors	O
,	O
lymph	B:C0686619
node	I:C0686619
metastases	I:C0686619
(	O
lymph	O
node	I:C0686619
metastases	I:C0686619
)	O
and	O
distant	O
metastases	I:C1269798
.	O

To	O
evaluate	O
the	O
frequency	O
of	O
TERT	O
promoter	O
(	O
TERT	O
promoter	I:C0314621
)	O
,	O
BRAF	O
and	O
NRAS	O
mutations	O
in	O
metastatic	O
thyroid	O
carcinomas	I:C0549473
,	O
analyzing	O
primary	O
thyroid	O
tumors	O
,	O
lymph	O
node	I:C0686619
metastases	I:C0686619
(	O
lymph	B:C0686619
node	I:C0686619
metastases	I:C0686619
)	O
and	O
distant	O
metastases	I:C1269798
.	O

To	O
evaluate	O
the	O
frequency	O
of	O
TERT	O
promoter	O
(	O
TERT	O
promoter	I:C0314621
)	O
,	O
BRAF	O
and	O
NRAS	O
mutations	O
in	O
metastatic	O
thyroid	O
carcinomas	I:C0549473
,	O
analyzing	O
primary	O
thyroid	O
tumors	O
,	O
lymph	O
node	I:C0686619
metastases	I:C0686619
(	O
lymph	O
node	I:C0686619
metastases	I:C0686619
)	O
and	O
distant	B:C1269798
metastases	I:C1269798
.	O

Mutation	B:C0796357
analysis	I:C0796357
was	O
performed	O
in	O
437	O
tissue	O
samples	I:C0475358
from	O
204	O
patients	O
,	O
mainly	O
with	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
(	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
)	O
(	O
n=180	O
)	O
,	O
including	O
196	O
lymph	O
node	I:C0686619
metastases	I:C0686619
and	O
56	O
distant	O
metastases	I:C1269798
.	O

Mutation	O
analysis	I:C0796357
was	O
performed	O
in	O
437	O
tissue	B:C0475358
samples	I:C0475358
from	O
204	O
patients	O
,	O
mainly	O
with	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
(	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
)	O
(	O
n=180	O
)	O
,	O
including	O
196	O
lymph	O
node	I:C0686619
metastases	I:C0686619
and	O
56	O
distant	O
metastases	I:C1269798
.	O

Mutation	O
analysis	I:C0796357
was	O
performed	O
in	O
437	O
tissue	O
samples	I:C0475358
from	O
204	O
patients	O
,	O
mainly	O
with	O
papillary	B:C0238463
thyroid	I:C0238463
carcinomas	I:C0238463
(	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
)	O
(	O
n=180	O
)	O
,	O
including	O
196	O
lymph	O
node	I:C0686619
metastases	I:C0686619
and	O
56	O
distant	O
metastases	I:C1269798
.	O

Mutation	O
analysis	I:C0796357
was	O
performed	O
in	O
437	O
tissue	O
samples	I:C0475358
from	O
204	O
patients	O
,	O
mainly	O
with	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
(	O
papillary	B:C0238463
thyroid	I:C0238463
carcinomas	I:C0238463
)	O
(	O
n=180	O
)	O
,	O
including	O
196	O
lymph	O
node	I:C0686619
metastases	I:C0686619
and	O
56	O
distant	O
metastases	I:C1269798
.	O

Mutation	O
analysis	I:C0796357
was	O
performed	O
in	O
437	O
tissue	O
samples	I:C0475358
from	O
204	O
patients	O
,	O
mainly	O
with	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
(	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
)	O
(	O
n=180	O
)	O
,	O
including	O
196	O
lymph	B:C0686619
node	I:C0686619
metastases	I:C0686619
and	O
56	O
distant	O
metastases	I:C1269798
.	O

Mutation	O
analysis	I:C0796357
was	O
performed	O
in	O
437	O
tissue	O
samples	I:C0475358
from	O
204	O
patients	O
,	O
mainly	O
with	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
(	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
)	O
(	O
n=180	O
)	O
,	O
including	O
196	O
lymph	O
node	I:C0686619
metastases	I:C0686619
and	O
56	O
distant	B:C1269798
metastases	I:C1269798
.	O

All	O
the	O
distant	B:C1269798
metastases	I:C1269798
included	O
corresponded	O
to	O
radioiodine	O
-	O
refractory	O
metastatic	O
tissue	O
.	O

All	O
the	O
distant	O
metastases	I:C1269798
included	O
corresponded	O
to	O
radioiodine	B:C1441129
-	O
refractory	O
metastatic	O
tissue	O
.	O

All	O
the	O
distant	O
metastases	I:C1269798
included	O
corresponded	O
to	O
radioiodine	O
-	O
refractory	O
metastatic	B:C0027627
tissue	O
.	O

All	O
the	O
distant	O
metastases	I:C1269798
included	O
corresponded	O
to	O
radioiodine	O
-	O
refractory	O
metastatic	O
tissue	B:C0040300
.	O

We	O
found	O
the	O
following	O
mutation	O
frequency	O
in	O
primary	B:C0677930
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
,	O
lymph	O
node	I:C0686619
metastases	I:C0686619
and	O
distant	O
metastases	I:C1269798
,	O
respectively	O
:	O
TERT	O
promoter	I:C0314621
-	O
12.9	O
%	O
,	O
10.5	O
%	O
,	O
and	O
52.4	O
%	O
;	O
BRAF	O
-	O
44.6	O
%	O
,	O
41.7	O
%	O
,	O
and	O
23.8	O
%	O
;	O
NRAS	O
-	O
1.2	O
%	O
,	O
1.3	O
%	O
,	O
and	O
14.3	O
%	O
.	O

We	O
found	O
the	O
following	O
mutation	O
frequency	O
in	O
primary	O
papillary	B:C0238463
thyroid	I:C0238463
carcinomas	I:C0238463
,	O
lymph	O
node	I:C0686619
metastases	I:C0686619
and	O
distant	O
metastases	I:C1269798
,	O
respectively	O
:	O
TERT	O
promoter	I:C0314621
-	O
12.9	O
%	O
,	O
10.5	O
%	O
,	O
and	O
52.4	O
%	O
;	O
BRAF	O
-	O
44.6	O
%	O
,	O
41.7	O
%	O
,	O
and	O
23.8	O
%	O
;	O
NRAS	O
-	O
1.2	O
%	O
,	O
1.3	O
%	O
,	O
and	O
14.3	O
%	O
.	O

We	O
found	O
the	O
following	O
mutation	O
frequency	O
in	O
primary	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
,	O
lymph	B:C0686619
node	I:C0686619
metastases	I:C0686619
and	O
distant	O
metastases	I:C1269798
,	O
respectively	O
:	O
TERT	O
promoter	I:C0314621
-	O
12.9	O
%	O
,	O
10.5	O
%	O
,	O
and	O
52.4	O
%	O
;	O
BRAF	O
-	O
44.6	O
%	O
,	O
41.7	O
%	O
,	O
and	O
23.8	O
%	O
;	O
NRAS	O
-	O
1.2	O
%	O
,	O
1.3	O
%	O
,	O
and	O
14.3	O
%	O
.	O

We	O
found	O
the	O
following	O
mutation	O
frequency	O
in	O
primary	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
,	O
lymph	O
node	I:C0686619
metastases	I:C0686619
and	O
distant	B:C1269798
metastases	I:C1269798
,	O
respectively	O
:	O
TERT	O
promoter	I:C0314621
-	O
12.9	O
%	O
,	O
10.5	O
%	O
,	O
and	O
52.4	O
%	O
;	O
BRAF	O
-	O
44.6	O
%	O
,	O
41.7	O
%	O
,	O
and	O
23.8	O
%	O
;	O
NRAS	O
-	O
1.2	O
%	O
,	O
1.3	O
%	O
,	O
and	O
14.3	O
%	O
.	O

We	O
found	O
the	O
following	O
mutation	O
frequency	O
in	O
primary	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
,	O
lymph	O
node	I:C0686619
metastases	I:C0686619
and	O
distant	O
metastases	I:C1269798
,	O
respectively	O
:	O
TERT	B:C0314621
promoter	I:C0314621
-	O
12.9	O
%	O
,	O
10.5	O
%	O
,	O
and	O
52.4	O
%	O
;	O
BRAF	O
-	O
44.6	O
%	O
,	O
41.7	O
%	O
,	O
and	O
23.8	O
%	O
;	O
NRAS	O
-	O
1.2	O
%	O
,	O
1.3	O
%	O
,	O
and	O
14.3	O
%	O
.	O

We	O
found	O
the	O
following	O
mutation	O
frequency	O
in	O
primary	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
,	O
lymph	O
node	I:C0686619
metastases	I:C0686619
and	O
distant	O
metastases	I:C1269798
,	O
respectively	O
:	O
TERT	O
promoter	I:C0314621
-	O
12.9	O
%	O
,	O
10.5	O
%	O
,	O
and	O
52.4	O
%	O
;	O
BRAF	B:C0812241
-	O
44.6	O
%	O
,	O
41.7	O
%	O
,	O
and	O
23.8	O
%	O
;	O
NRAS	O
-	O
1.2	O
%	O
,	O
1.3	O
%	O
,	O
and	O
14.3	O
%	O
.	O

We	O
found	O
the	O
following	O
mutation	O
frequency	O
in	O
primary	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
,	O
lymph	O
node	I:C0686619
metastases	I:C0686619
and	O
distant	O
metastases	I:C1269798
,	O
respectively	O
:	O
TERT	O
promoter	I:C0314621
-	O
12.9	O
%	O
,	O
10.5	O
%	O
,	O
and	O
52.4	O
%	O
;	O
BRAF	O
-	O
44.6	O
%	O
,	O
41.7	O
%	O
,	O
and	O
23.8	O
%	O
;	O
NRAS	B:C0027260
-	O
1.2	O
%	O
,	O
1.3	O
%	O
,	O
and	O
14.3	O
%	O
.	O

There	O
was	O
a	O
significant	O
concordance	O
between	O
the	O
primary	B:C0677930
tumor	I:C0677930
genotype	O
and	O
the	O
corresponding	O
lymph	O
node	I:C0686619
metastases	I:C0686619
for	O
all	O
the	O
genes	O
,	O
in	O
particular	O
BRAF	O
-	O
mutated	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
.	O

There	O
was	O
a	O
significant	O
concordance	O
between	O
the	O
primary	O
tumor	I:C0677930
genotype	O
and	O
the	O
corresponding	O
lymph	B:C0686619
node	I:C0686619
metastases	I:C0686619
for	O
all	O
the	O
genes	O
,	O
in	O
particular	O
BRAF	O
-	O
mutated	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
.	O

There	O
was	O
a	O
significant	O
concordance	O
between	O
the	O
primary	O
tumor	I:C0677930
genotype	O
and	O
the	O
corresponding	O
lymph	O
node	I:C0686619
metastases	I:C0686619
for	O
all	O
the	O
genes	B:C0017337
,	O
in	O
particular	O
BRAF	O
-	O
mutated	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
.	O

There	O
was	O
a	O
significant	O
concordance	O
between	O
the	O
primary	O
tumor	I:C0677930
genotype	O
and	O
the	O
corresponding	O
lymph	O
node	I:C0686619
metastases	I:C0686619
for	O
all	O
the	O
genes	O
,	O
in	O
particular	O
BRAF	B:C0812241
-	O
mutated	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
.	O

There	O
was	O
a	O
significant	O
concordance	O
between	O
the	O
primary	O
tumor	I:C0677930
genotype	O
and	O
the	O
corresponding	O
lymph	O
node	I:C0686619
metastases	I:C0686619
for	O
all	O
the	O
genes	O
,	O
in	O
particular	O
BRAF	O
-	O
mutated	O
papillary	B:C0238463
thyroid	I:C0238463
carcinomas	I:C0238463
.	O

The	O
overall	O
concordance	O
between	O
primary	B:C0677930
tumors	I:C0677930
and	O
respective	O
distant	O
metastases	I:C1269798
was	O
low	O
.	O

The	O
overall	O
concordance	O
between	O
primary	O
tumors	I:C0677930
and	O
respective	O
distant	B:C1269798
metastases	I:C1269798
was	O
low	O
.	O

In	O
the	O
group	O
of	O
patients	O
with	O
papillary	B:C0238463
thyroid	I:C0238463
carcinomas	I:C0238463
,	O
we	O
found	O
a	O
high	O
frequency	O
of	O
TERT	O
promoter	I:C0314621
mutations	O
and	O
a	O
low	O
frequency	O
of	O
BRAF	O
mutations	O
in	O
distant	O
metastases	I:C1269798
,	O
in	O
comparison	O
to	O
the	O
paired	O
primary	O
tumors	I:C0677930
.	O

In	O
the	O
group	O
of	O
patients	O
with	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
,	O
we	O
found	O
a	O
high	O
frequency	O
of	O
TERT	B:C0314621
promoter	I:C0314621
mutations	O
and	O
a	O
low	O
frequency	O
of	O
BRAF	O
mutations	O
in	O
distant	O
metastases	I:C1269798
,	O
in	O
comparison	O
to	O
the	O
paired	O
primary	O
tumors	I:C0677930
.	O

In	O
the	O
group	O
of	O
patients	O
with	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
,	O
we	O
found	O
a	O
high	O
frequency	O
of	O
TERT	O
promoter	I:C0314621
mutations	B:C1516197
and	O
a	O
low	O
frequency	O
of	O
BRAF	O
mutations	O
in	O
distant	O
metastases	I:C1269798
,	O
in	O
comparison	O
to	O
the	O
paired	O
primary	O
tumors	I:C0677930
.	O

In	O
the	O
group	O
of	O
patients	O
with	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
,	O
we	O
found	O
a	O
high	O
frequency	O
of	O
TERT	O
promoter	I:C0314621
mutations	O
and	O
a	O
low	O
frequency	O
of	O
BRAF	B:C0812241
mutations	O
in	O
distant	O
metastases	I:C1269798
,	O
in	O
comparison	O
to	O
the	O
paired	O
primary	O
tumors	I:C0677930
.	O

In	O
the	O
group	O
of	O
patients	O
with	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
,	O
we	O
found	O
a	O
high	O
frequency	O
of	O
TERT	O
promoter	I:C0314621
mutations	O
and	O
a	O
low	O
frequency	O
of	O
BRAF	O
mutations	B:C1516197
in	O
distant	O
metastases	I:C1269798
,	O
in	O
comparison	O
to	O
the	O
paired	O
primary	O
tumors	I:C0677930
.	O

In	O
the	O
group	O
of	O
patients	O
with	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
,	O
we	O
found	O
a	O
high	O
frequency	O
of	O
TERT	O
promoter	I:C0314621
mutations	O
and	O
a	O
low	O
frequency	O
of	O
BRAF	O
mutations	O
in	O
distant	B:C1269798
metastases	I:C1269798
,	O
in	O
comparison	O
to	O
the	O
paired	O
primary	O
tumors	I:C0677930
.	O

In	O
the	O
group	O
of	O
patients	O
with	O
papillary	O
thyroid	I:C0238463
carcinomas	I:C0238463
,	O
we	O
found	O
a	O
high	O
frequency	O
of	O
TERT	O
promoter	I:C0314621
mutations	O
and	O
a	O
low	O
frequency	O
of	O
BRAF	O
mutations	O
in	O
distant	O
metastases	I:C1269798
,	O
in	O
comparison	O
to	O
the	O
paired	O
primary	B:C0677930
tumors	I:C0677930
.	O

When	O
present	O
in	O
distant	B:C1269798
metastases	I:C1269798
,	O
BRAF	O
mutations	O
frequently	O
coexisted	O
with	O
TERT	O
promoter	I:C0314621
mutations	O
.	O

When	O
present	O
in	O
distant	O
metastases	I:C1269798
,	O
BRAF	B:C0812241
mutations	O
frequently	O
coexisted	O
with	O
TERT	O
promoter	I:C0314621
mutations	O
.	O

When	O
present	O
in	O
distant	O
metastases	I:C1269798
,	O
BRAF	O
mutations	B:C1516197
frequently	O
coexisted	O
with	O
TERT	O
promoter	I:C0314621
mutations	O
.	O

When	O
present	O
in	O
distant	O
metastases	I:C1269798
,	O
BRAF	O
mutations	O
frequently	O
coexisted	O
with	O
TERT	B:C0314621
promoter	I:C0314621
mutations	O
.	O

When	O
present	O
in	O
distant	O
metastases	I:C1269798
,	O
BRAF	O
mutations	O
frequently	O
coexisted	O
with	O
TERT	O
promoter	I:C0314621
mutations	B:C1516197
.	O

When	O
the	O
genotype	O
of	O
primary	B:C0677930
tumors	I:C0677930
is	O
compared	O
with	O
the	O
genotype	O
of	O
lymph	O
node	I:C0686619
metastases	I:C0686619
,	O
the	O
concordance	O
is	O
high	O
for	O
all	O
the	O
genes	O
studied	O
.	O

When	O
the	O
genotype	O
of	O
primary	O
tumors	I:C0677930
is	O
compared	O
with	O
the	O
genotype	O
of	O
lymph	B:C0686619
node	I:C0686619
metastases	I:C0686619
,	O
the	O
concordance	O
is	O
high	O
for	O
all	O
the	O
genes	O
studied	O
.	O

When	O
the	O
genotype	O
of	O
primary	O
tumors	I:C0677930
is	O
compared	O
with	O
the	O
genotype	O
of	O
lymph	O
node	I:C0686619
metastases	I:C0686619
,	O
the	O
concordance	O
is	O
high	O
for	O
all	O
the	O
genes	B:C0017337
studied	O
.	O

On	O
the	O
other	O
hand	O
,	O
distant	B:C1269798
metastases	I:C1269798
show	O
an	O
enrichment	O
in	O
TERT	O
promoter	I:C0314621
mutations	O
and	O
a	O
decrease	O
in	O
BRAF	O
mutations	O
.	O

On	O
the	O
other	O
hand	O
,	O
distant	O
metastases	I:C1269798
show	O
an	O
enrichment	O
in	O
TERT	B:C0314621
promoter	I:C0314621
mutations	O
and	O
a	O
decrease	O
in	O
BRAF	O
mutations	O
.	O

On	O
the	O
other	O
hand	O
,	O
distant	O
metastases	I:C1269798
show	O
an	O
enrichment	O
in	O
TERT	O
promoter	I:C0314621
mutations	B:C1516197
and	O
a	O
decrease	O
in	O
BRAF	O
mutations	O
.	O

On	O
the	O
other	O
hand	O
,	O
distant	O
metastases	I:C1269798
show	O
an	O
enrichment	O
in	O
TERT	O
promoter	I:C0314621
mutations	O
and	O
a	O
decrease	O
in	O
BRAF	B:C0812241
mutations	O
.	O

On	O
the	O
other	O
hand	O
,	O
distant	O
metastases	I:C1269798
show	O
an	O
enrichment	O
in	O
TERT	O
promoter	I:C0314621
mutations	O
and	O
a	O
decrease	O
in	O
BRAF	O
mutations	B:C1516197
.	O

TERT	B:C0314621
promoter	I:C0314621
mutations	O
may	O
play	O
a	O
role	O
in	O
distant	O
metastases	I:C1269798
.	O

TERT	O
promoter	I:C0314621
mutations	B:C1516197
may	O
play	O
a	O
role	O
in	O
distant	O
metastases	I:C1269798
.	O

TERT	O
promoter	I:C0314621
mutations	O
may	O
play	O
a	O
role	O
in	O
distant	B:C1269798
metastases	I:C1269798
.	O

